Technology evaluation: Onyvax-P, Onyvax.

Abstract	Onyvax is developing Onyvax-P, an allogeneic whole-cell vaccine, for the potential treatment of prostate cancer. The vaccine is currently undergoing phase II clinical trials.
Authors	Christian Doehn, Torsten Böhmer, Dieter Jocham
Journal	Current opinion in molecular therapeutics (Curr Opin Mol Ther) Vol. 7 Issue 5 Pg. 511-9 (Oct 2005) ISSN: 1464-8431 [Print] England
PMID	16248287 (Publication Type: Journal Article, Review)
Chemical References	Cancer Vaccines Onyvax-P
Topics	Animals Cancer Vaccines (adverse effects, therapeutic use) Cell Line, Tumor Clinical Trials, Phase I as Topic Clinical Trials, Phase II as Topic Contraindications Drug Evaluation, Preclinical Humans Male Prostatic Neoplasms (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!